Cell Line Development News Today

WILMINGTON, Mass. and OKLAHOMA CITY, Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization , announced today a new strategic agreement with...

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to their clients, to convert the drug substance produced at its state-of-the-art Adelaide, South Australia facility into ready-to

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The

Scientists at J&J are using the Intabio ZT system for enhanced monoclonal antibody development

Scientists at J&J are using the Intabio ZT system for enhanced monoclonal antibody development

This technical note highlights a streamlined solution to monitor antibody discoloration using an EAD-based MAM workflow

Abzena, an end-to-end CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms to accelerate cell lie production for manufacturing antibodies and recombinant proteins.

Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The

The global Cell Line Development Industry is poised for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period. According to the latest market insights, total cell line product sales are expected to reach US$ 3,124.4 million in 2023, and a staggering US$ 4,674.8...

The global Cell Line Development market is anticipated to grow at a CAGR of 9.6% during the forecast period (2023-2030).